Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript April 23, 2024 Kiniksa Pharmaceuticals, Ltd. beats earnings expectations. Reported EPS is $-0.00025, expectations were $-0.14. KNSA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
Those skeptical of the assertion that COVID-19 vaccines were altogether safe and effective a claim long advanced by once-trusted government agencies, pharmaceutical companies, and the media amidst a historic censorship campaign targeting dissenters and critics appear to have had their doubts.
The researchers cautioned that the study found only associations with adverse health effects and it does not prove that these issues are caused by the vaccines.
Patients who took some coronavirus vaccines faced a slightly higher risk of medical conditions like myocarditis and pericarditis but people who contract the coronavirus face a greater risk.